Back to search

National and Kapodistrian University of Athens

Διερεύνηση του μοριακού μονοπατιού και της κλινικής συσχέτισης του αυξητικού παράγοντα της ινσουλίνης τύπου Ι σε ασθενείς με προχωρημένο μη μικροκυτταρικό καρκίνο πνεύμονα

Abstract

dc:description

Insulin-like growth factor 1(IGF-1) signaling pathway has been suggested as an important oncogenic mediator in various malignancies, including lung cancer. In this study, we aimed to evaluate serum levels of IGF-1, IGF-2 and IGF Binding Protein 3 (IGF-BP3) before and after chemotherapy or chemoradiotherapy treatment in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) and their potential correlation with response to therapy and patient survival. Methods: Seventy-three patients with stage III/IV NSCLC were included in the study. Expression of IGF1, IGF2, and IGFBP3 was evaluated in peripheral blood samples in two separate time points, at baseline and 3 months post treatment. Analysis and quantification of circulating levels of IGF-1, IGF-2, IGF-BP3 were performed by total ELISA technique. IGF-1/IGF-BP3 ratio is considered an indicator of IGF-1bioavailability. Results: In univariate analysis, the median value of IGF-1 after treatment (130.80 vs 98.00 ng/ml, p=0.087), and the median ratio of IGF-1/IGF-BP3 (0.01044 vs 0.00678,p=0.056) were higher in responders. Further analysis of the variation of each biomarker before and after treatment showed that the median value of IGF-1 was decreased after treatment in the total population (125.82 from 133.4 ng/ml, p=0.087), albeit no difference was found between subgroups. In addition, the median value of IGF-1/IGF-BP3 ratio was found to be lower after treatment in the total population (0.01006 from 0.01252, p=0.011). Importantly, the post-treatment value of the ratio was significantly reduced in responders (0.01044 from 0.01255, p=0.02). No correlation was found between variation in biomarker values, patient OS and PFS. Conclusions: In a cohort of patients with stage III/IV NSCLC treated with chemotherapy or chemoradiotherapy, reduction of IGF-1/IGF-BP3 ratio, which is anindicator of IGF-1 bioavailability, was statistically significant in patients that responded to treatment. If validated in larger cohorts, our results support the use ofIGF-1/IGFBP3 as a predictive tool for response to chemotherapy in NSCLC.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kotsantis, Ioannis
  • Κωτσαντής, Ιωάννης

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/46637

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kotsantis, Ioannis; Κωτσαντής, Ιωάννης. Διερεύνηση του μοριακού μονοπατιού και της κλινικής συσχέτισης του αυξητικού παράγοντα της ινσουλίνης τύπου Ι σε ασθενείς με προχωρημένο μη μικροκυτταρικό καρκίνο πνεύμονα. National and Kapodistrian University of Athens, 2019. http://hdl.handle.net/10442/hedi/46637